‘Fire and forget?’ — pharmacological considerations in coronary care

This publication has 36 references indexed in Scilit:

• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
  European Heart Journal, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
  British Journal of Clinical Pharmacology, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
  The Lancet, 1994
• Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors, and outcome
  The American Journal of Medicine, 1993
• Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia
  Gastroenterology, 1992